For the nine months ended September 30, 2008, total operating revenuesincreased by 2.0% to $1,428,753 from $1,400,747 for the same period in2007. Four Blood Volume Analyzers were sold in the nine months endedSeptember 30, 2008 for a total of $260,000 versus the sale of fiveinstruments for the same period in 2007 for a total of $325,500. TheCenters for Medicare and Medicaid Services (CMS) implemented a policychange effective January 1, 2008 which significantly reduced thereimbursement for diagnostic radiopharmaceutical products. It is theopinion of management that this change has negatively impacted instrumentsales. For the nine months ended September 30, 2008, Volumex kit salesincreased by $112,201 or 16.5%. For the nine months ended September 30,2008, total costs and expenses decreased by 4.9% to $5,143,528 from$5,409,714 for the same period in 2007.

At September 30, 2008, the Company had total assets of $91,761,470 withtotal stockholders' equity of $53,628,415 versus total assets of$102,560,500 and $54,915,885 of stockholders' equity at December 31, 2007.In the first three and nine months of 2008 and 2007, the company hadsignificant income from investments which completely offset the operatingloss.

Total other income for the nine months ended September 30, 2008 increasedby 90.7% to $21,666,967 from $11,364,479 for the same period in 2007. Thebasic net income per share for the nine months ended September 30, 2008 was$3.49 versus $1.60 for the same period in 2007.

The company is continuing its efforts associated with research anddevelopment as part of the ongoing effort to develop products that arecomplementary to its current product line. The improvement in the company'sfinancial structure is important for the company's expansion plans. Therewere 53 Blood Volume Analyzers placed at September 30, 2008 versus 55instruments at September 30, 2007.

One of the clinical outcome studies that the Company has begun this yearfocuses on utilizing the Blood Volume Analyzer BVA-100 to guide therapy forheart failure patients undergoing ultrafiltration treatment to achieve anormal volume status. Ultrafiltration is a therapy which removes fluidfrom a patient, similar to dialysis. Removal of inadequate quantities offluid in some heart failure patients has been associated with pooroutcomes. Removal of excess quantities of fluid may result in kidneydamage. However, achievement to a normal volume status has been adifficult parameter to achieve without a measured blood volume. This veryimportant prospective outcome study will be conducted at ChristianaHospital of Newark, Delaware.

As a result of The Board of Directors voting to enact a policy of payingquarterly dividends of $0.25 per share, a dividend will be paid on November26, 2008 in addition to the previous dividend paid on August 27, 2008. TheBoard of Directors will meet during the latter part of November to reviewthe possibility of paying a special dividend in December of 2008. TheCompany intends to continue a policy of paying dividends on a quarterlybasis if net income is available to maintain the dividend.

Under the provisions of the Company's stock buyback program, Daxor maypurchase up to 250,000 shares of the Company's common stock each year. Aspart of this program, the Company purchased 166,400 shares of Daxor CommonStock during the nine months ended September 30, 2008 and 163,808 duringthe year ended December 31, 2007.

Three Months Ended Nine Months Ended September 30 September 30 2008 2007 2008 2007 ----------- ----------- ----------- -----------Total Operating Revenues $ 451,253 $ 349,547 $ 1,428,753 $ 1,400,747Total Costs & Expenses $ 1,672,976 $ 1,918,386 $ 5,143,528 $ 5,409,714 ----------- ----------- ----------- -----------Net Loss from Operations $(1,221,723) $(1,568,839) $(3,714,775) $(4,008,967)Total Other Income $ 9,948,065 $ 3,524,442 $21,666,967 $11,364,479 ----------- ----------- ----------- -----------Net Income Before Income Taxes $ 8,726,342 $ 1,955,603 $17,952,192 $ 7,355,512Income Tax Expense $ 2,325,000 $ 0 $ 2,725,000 $ 0 ----------- ----------- ----------- -----------Net Income $ 6,401,342 $ 1,955,603 $15,227,192 $ 7,355,512 ----------- ----------- ----------- -----------Weighted Average Number Of Shares Outstanding- Basic 4,324,885 4,578,485 4,369,440 4,591,563Earnings Per Share- Basic $ 1.48 $ 0.43 $ 3.49 $ 1.60Weighted Average Number Of Shares Outstanding- Diluted 4,346,885 4,578,485 4,440,140 4,591,563Earnings Per Share- Diluted $ 1.47 $ 0.43 $ 3.43 $ 1.60

Contact Information:Daxor CorporationStephen Feldschuh212-330-8515(Chief Operating Officer)stephen@daxor.comDavid Frankel212-330-8504(Chief Financial Officer)dfrankel@daxor.com